에 대한 최신 뉴스 Cormedix (NASDAQ:CRMD) 주식

CORMEDIX INC

Cormedix

Cormedix Inc is a biopharmaceutical company focused on developing and commercializing therapeutic products for life-threatening diseases and conditions. The Company's focus is on the commercialization of its product, DefenCath, in the United States (U.S.) and other key markets. The group currently operates in a single segment, Drug Product, located in a single geographic location, the United States.

benzingaai2023_modern_computer_screen_with_stock_chart_stock__6576dd35-b4b0-42d8-8403-ba4e9845ab24_3

News

Hedge Funds

Trading Ideas

BILL

CFLT

CRMD

ICLR

MSTR

NVDA

RING

WOLF

엘리엇 인베스트먼트 매니지먼트는 4분기 동안 여러 포트폴리오 조정을 하였다. 여러 옵션 포지션을 청산하고 이 행동주의 투자 회사의 기술 노출을 재편했다. 미국 증권 거래 위원회에 제출된 새로운 13-F 파일링에 따르면, 엘리엇은 4분기에 다음과 같은 새로운 포지션을 추가했다:

엘리엇 인베스트먼트가 울프스피드 주식을 매수하고 4분기에는 엔비디아 풋 옵션에 베팅

Cormedix Inc

Needham analyst Serge Belanger maintains Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) with a Buy and raises the price target from $12 to $15.

Price Target

Analyst Ratings

Needham Maintains Buy on Cormedix, Raises Price Target to $15

D. Boral Capital analyst Jason Kolbert maintains Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) with a Buy and maintains $15 price target.

D. Boral Capital Maintains Buy on Cormedix, Maintains $15 Price Target

WIIM

CorMedix shares are trading higher after the company reported better-than-expected Q1 financial results.

<ul>
<li>CorMedix expects to be at the high-end of the previously announced first half net sales guidance of $62 million to $70 million, based on latest order trends and inventory tracking with current purchasing customers.</li>
</ul>

Guidance

Cormedix Expects To Be At High-End Of Previously Announced 1H Net Sales Guidance Of $62M-$70M

Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) reported quarterly earnings of $0.30 per share which beat the analyst consensus estimate of $0.24 by 25 percent. This is a 220 percent increase over losses of $(0.25) per share from the same period last year. The company reported quarterly sales of $39.08 million which beat the analyst consensus estimate of $36.00 million by 8.55 percent.

Earnings

Earnings Beats

Cormedix Q1 EPS $0.30 Beats $0.24 Estimate, Sales $39.08M Beat $36.00M Estimate

ACLS

AHCO

ALAB

ALGS

ALGT

AMTM

ANDE

ANET

ANGI

ARDT

ARIS

ARMK

ARQT

ARRY

ATKR

ATOM

ATRO

AUDC

AVNS

AVNT

AVNW

AZEK

BALL

BBNX

BCAB

BLDP

BRLT

BWIN

BWMN

CCCS

CCLD

CDRE

CELH

CGAU

CGBD

CHMI

CHRD

CIFR

CIGI

CLDT

CLOV

COTY

CPAY

CPIX

CPNG

CRCT

CRIS

CRSR

CRUS

CURI

CVGI

CXDO

CYTK

DASH

DAWN

DDOG

DOCN

DRCT

DRVN

DVAX

ENLT

EOSE

Embraer-Empresa Brasileira De Aeronautica

ESPR

EVGO

Earnings Scheduled For May 6, 2025

Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) is preparing to release its quarterly earnings on Tuesday, 2025-05-06. Here's a brief overview of what investors should keep in mind before the announcement.
Analysts expect Cormedix to report an earnings per share (EPS) of $0.23.
The announcement from Cormedix is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS beat by $0.08, leading to a 2.45% drop in the share price on the subsequent day.
Here's a look at Cormedix's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>0.14</td>
<td>-0.10</td>
<td>-0.25</td>
<td>-0.28</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>0.22</td>
<td>-0.05</td>
<td>-0.25</td>
<td>-0.25</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-2.0%</td>
<td>0.0%</td>
<td>-3.0%</td>
<td>-4.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746468176_0.png" alt="eps graph" />
<h3>Performance of Cormedix Shares</h3>
Shares of Cormedix were trading at $9.38 as of May 02. Over the last 52-week period, shares are up 53.6%. Given that these returns are generally positive, long-term shareholders should be satisfied going into this earnings release. 
<a href="https://www.benzinga.com/quote/CRMD/earnings">To track all earnings releases for Cormedix visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Earnings Preview For Cormedix

Needham analyst Serge Belanger reiterates Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) with a Buy and maintains $12 price target.

Reiteration

Needham Reiterates Buy on Cormedix, Maintains $12 Price Target

U.S. stocks were higher, with the Dow Jones index surging over 1,300 points on Tuesday.
Shares of Marvell Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVL#NASDAQ">MRVL</a>) rose sharply during Tuesday's session after Infineon Technologies agreed to acquire its Automotive Ethernet <a href="https://in.benzinga.com/25/04/44683383/marvell-plays-ai-hardball-divestiture-sparks-155-upside-says-analyst">Business for $2.5 billion in cash</a>.
The transaction includes Marvell&#8217;s Brightlane Automotive Ethernet portfolio and related assets. The company projected this segment to generate $225 million to $250 million in revenue in 2025, with a gross margin of around 60%.
Marvell Technology shares jumped 10.1% to $56.16 on Tuesday.
Here are some other big stocks recording gains in today's session.
<ul>
<li>agilon health, inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AGL#NYSE">AGL</a>) shares jumped 31.8% to $5.60.</li>
<li>NextDecade Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEXT#NASDAQ">NEXT</a>) gained 23.3% to $7.38 after the company announced a 20-year LNG sale and purchase agreement to supply 1.2 million tonnes per year to a subsidiary of Saudi Aramco.</li>
<li>Venture Global, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VG#NYSE">VG</a>) gained 21.4% to $8.50.</li>
<li>CorMedix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) shares rose 21.1% to $7.36 after the company issued first-quarter preliminary revenue guidance above estimates.</li>
<li>Pacira BioSciences, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PCRX#NASDAQ">PCRX</a>) gained 16.1% to $26.60 after HC Wainwright &amp; Co. raised its price target on the stock from $48 to $65 and maintained a Buy rating.</li>
<li>Alignment Healthcare, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ALHC#NASDAQ">ALHC</a>) jumped 14.9% to $20.48.</li>
<li>Uxin Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UXIN#NASDAQ">UXIN</a>) gained 14.7% to $3.9098.</li>
<li>Carvana Co. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVNA#NYSE">CVNA</a>) climbed 14.6% to $192.29.</li>
<li>Applied Optoelectronics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAOI#NASDAQ">AAOI</a>) rose 14% to $12.81.</li>
<li>ECARX Holdings Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ECX#NASDAQ">ECX</a>) gained 14% to $1.14 after the company announced it increased its share repurchase program by $20 million to $40 million.</li>
<li>Humana Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HUM#NYSE">HUM</a>) rose 12.3% to $286.14 following a WSJ report indicating the Trump administration will increase Medicare Advantage rates.</li>
<li>Rhythm Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RYTM#NASDAQ">RYTM</a>) gained 12.4% to $61.76. Canaccord Genuity analyst Whitney Ijem maintained Rhythm Pharmaceuticals with a Buy and raised the price target from $81 to $92.</li>
<li>Grab Holdings Limited (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GRAB#NASDAQ">GRAB</a>) rose 12.4% to $3.9150.</li>
<li>Sandisk Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNDK#NASDAQ">SNDK</a>) gained 12.4% to $35.40.</li>
<li>Western Digital Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WDC#NASDAQ">WDC</a>) rose 10% to $34.26.</li>
<li>AppLovin Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/APP#NASDAQ">APP</a>) gained 10% to $255.36.</li>
<li>CVS Health Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>) rose 8.5% to $69.29 after the company announced changes to management and Medicare increased advantage payment rates.</li>
<li>NVIDIA Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>) gained 7.9% to $105.39.</li>
<li>Shopify Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHOP#NYSE">SHOP</a>) rose 7.8% to $85.05.</li>
<li>Tesla, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TSLA#NASDAQ">TSLA</a>) gained 6.3% to $248.09.</li>
<li>Apple Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>) rose 4.2% to $189.13. U.S. consumers are reportedly rushing to Apple stores to purchase new iPhones ahead of potential price hikes caused by President Donald Trump&#8217;s newly announced tariffs on Chinese imports.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/news/earnings/25/04/44682968/how-to-earn-500-a-month-from-delta-air-lines-stock-ahead-of-q1-earnings">How To Earn $500 A Month From Delta Air Lines Stock Ahead Of Q1 Earnings</a> </li>
</ul>
Photo via Shutterstock

Intraday Update

Markets

Movers

AAOI

AAPL

ALHC

CVNA

GRAB

MRVL

PCRX

RYTM

SHOP

SNDK

TSLA

UXIN

Marvell Technology, Nvidia, Tesla, Apple And Other Big Stocks Moving Higher On Tuesday

CorMedix shares are trading higher after the company issued Q1 preliminary revenue guidance above estimates.

<ul>
<li>Since providing initial guidance, the Company received larger than expected orders during the final week of March, and has also obtained additional visibility into inventory levels on hand at some of our current purchasing customers. Based on this new information, CorMedix is increasing its H1 2025 guidance for Net Sales to existing purchasing customers to a revised range of $62 million to $70 million.</li>
<li>While the Company is currently forecasting net sales from existing purchasing customers in 2Q 2025 to be lower than 1Q 2025, this is due to the timing of shipments to those customers between quarters, and does not suggest an anticipated decrease in patient utilization in the second quarter or the second half of 2025. CorMedix currently forecasts patient utilization with existing purchasing customers to continue to grow throughout 2025 as implementation expands to new patients, and currently anticipates unit shipments in H2 2025 to exceed shipments in H1 2025.</li>
<li>CorMedix expects patient enrollment for our Phase 3 study of DefenCath in patients receiving Total Parenteral Nutrition, or TPN, to begin in late April. The Company believes DefenCath, if approved for this indication, can achieve peak annual sales in this patient population of $150 million to $200 million, with a total addressable market opportunity of $500 million to $750 million.</li>
<li>Cash and short-term investments, excluding restricted cash, at March 31, 2025 amounted to approximately $77.5 million</li>
</ul>

Health Care

General

CorMedix Announces Preliminary Revenue Of $39M For 1Q 2025 Vs. Consensus Of $32.20M, And Expects 1Q 2025 Adjusted EBITDA (To Exceed $22.5M Once Final Numbers Are Reported)

RBC Capital analyst Gregory Renza reiterates Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) with a Outperform and maintains $12 price target.

RBC Capital Reiterates Outperform on Cormedix, Maintains $12 Price Target

Needham analyst Serge Belanger maintains Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) with a Buy and lowers the price target from $18 to $12.

Needham Maintains Buy on Cormedix, Lowers Price Target to $12

<h3>Gainers</h3>
<ul>
<li>Tenon Medical (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) stock rose 300.3% to $3.92 during Tuesday's regular session. The market value of their outstanding shares is at $12.2 million. As per the press release, Q4 earnings came out 3 days ago. </li>
<li>Predictive Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/POAI#NASDAQ">POAI</a>) stock rose 72.19% to $1.92. The company's market cap stands at $13.8 million. </li>
<li>ProPhase Labs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRPH#NASDAQ">PRPH</a>) stock rose 31.6% to $0.56. The market value of their outstanding shares is at $17.0 million. </li>
<li>Forte Biosciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FBRX#NASDAQ">FBRX</a>) shares increased by 25.71% to $7.95. The market value of their outstanding shares is at $50.7 million. </li>
<li>IO Biotech (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IOBT#NASDAQ">IOBT</a>) stock increased by 24.61% to $1.25. The company's market cap stands at $82.1 million. </li>
<li>Zhengye Biotechnology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ZYBT#NASDAQ">ZYBT</a>) shares rose 21.55% to $7.05. The market value of their outstanding shares is at $334.1 million. </li>
</ul>
<h3>Losers</h3>
<ul>
<li>CNS Pharma (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) stock declined by 59.8% to $1.36 during Tuesday's regular session. The market value of their outstanding shares is at $2.0 million. </li>
<li>Mural Oncology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) shares declined by 59.27% to $1.56. The company's market cap stands at $26.8 million. </li>
<li>IMAC Hldgs (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BACK#NASDAQ">BACK</a>) shares declined by 59.05% to $0.17. </li>
<li>Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) shares decreased by 33.8% to $7.13. The company's market cap stands at $432.6 million. The company's, Q4 earnings came out today. </li>
<li>Cassava Sciences (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SAVA#NASDAQ">SAVA</a>) stock decreased by 32.33% to $1.9. The market value of their outstanding shares is at $91.1 million. </li>
<li>Galecto (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GLTO#NASDAQ">GLTO</a>) stock decreased by 23.88% to $5.1. The company's market cap stands at $6.6 million. The company's, Q4 earnings came out 4 days ago. 
See Also: <a href="http://www.benzinga.com/money/best-healthcare-stocks/" title="www.benzinga.com/money/best-healthcare-stocks/">www.benzinga.com/money/best-healthcare-stocks/</a></li>
</ul>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

BACK

CNSP

FBRX

GLTO

IOBT

MURA

POAI

PRPH

SAVA

TNON

ZYBT

12 Health Care Stocks Moving In Tuesday's Intraday Session

U.S. stocks traded mixed midway through trading, with the Nasdaq Composite gaining around 50 points on Tuesday.
The Dow traded down 0.06% to 42,556.82 while the NASDAQ climbed 0.29% to 18,241.49. The S&amp;P 500 also rose, gaining, 0.06% to 5,770.81.
Check This Out: <a href="https://www.benzinga.com/25/03/44471817/top-2-health-care-stocks-that-are-ticking-portfolio-bombs-3">Top 2 Health Care Stocks That Are Ticking Portfolio Bombs</a>
Leading and Lagging Sectors Communication services shares jumped by 1.3% on Tuesday.
In trading on Tuesday, utilities shares fell by 1.6%.
Top Headline
Sales of new single-family homes increased 1.8% to an annual rate of 676,000 in February, following a revised 6.9% decline in the previous month, and down from market estimates of 680,000.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul>
<li>Tenon Medical, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TNON#NASDAQ">TNON</a>) shares shot up 287% to $3.79 on possible continued strength after the company announced yesterday that it has received FDA 510(k) clearance for its Catamaran St Joint Fusion System.</li>
<li>Shares of DatChat, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DATS#NASDAQ">DATS</a>)got a boost, surging 140% to $5.18 after the company announced its Myseum social media platform is available on Apple iOS and Android.</li>
<li>BitFuFu Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FUFU#NASDAQ">FUFU</a>) shares were also up, gaining 12% to $4.9970 after the company reported a FY24 GAAP EPS beat.</li>
</ul>
Equities Trading DOWN
<ul>
<li>Mural Oncology plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MURA#NASDAQ">MURA</a>) shares dropped 58% to $1.6050 after the company announced it will discontinue its final analysis of Nemvaleukin in combination with KEYTRUDA and will cease further development. Jones Trading downgraded the stock from Buy to Hold.</li>
<li>Shares of CNS Pharmaceuticals, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CNSP#NASDAQ">CNSP</a>) were down 60% to $1.3499 after the company announced primary analysis of Berubicin in second line treatment of glioblastoma multiforme.</li>
<li>CorMedix Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) was down, falling 32% to $7.32 following fourth-quarter results.</li>
</ul>
Commodities In commodity news, oil traded up 0.6% to $69.50 while gold traded up 0.7% at $3,037.10.
Silver traded up 2.4% to $34.235 on Tuesday, while copper rose 1.8% to $5.1825.
Euro zone
European shares were higher today. The eurozone's STOXX 600 gained 0.76%, Germany's DAX 40 rose 0.80% and France's CAC 40 rose 1.02%. Spain's IBEX 35 Index rose 1.10%, while London's FTSE 100 gained 0.74%.
Asia Pacific Markets
Asian markets closed mixed on Tuesday, with Japan's Nikkei 225 gaining 0.46%, China's Shanghai Composite Index falling 0.002%, Hong Kong's Hang Seng Index falling 2.35% and India's BSE Sensex gaining 0.04%.
Economics
<ul>
<li>The S&amp;P CoreLogic Case-Shiller home price index increased 4.7% year-over-year in January, versus a 4.5% increase in December, but down from market estimates of a 4.8% increase.</li>
<li>The FHFA house price index rose by 0.2% in January.</li>
<li>Sales of new single-family homes increased 1.8% to an annual rate of 676,000 in February, following a revised 6.9% decline in the previous month, and down from market estimates of 680,000.</li>
</ul>
Now Read This: 
<ul>
<li><a href="https://www.benzinga.com/25/03/44472214/wall-streets-most-accurate-analysts-spotlight-on-3-industrials-stocks-delivering-high-dividend-yields-4">Wall Street&#8217;s Most Accurate Analysts Spotlight On 3 Industrials Stocks Delivering High-Dividend Yields</a></li>
</ul>
Image: Shutterstock

Equities

Eurozone

Commodities

DATS

FUFU

Nasdaq Gains 50 Points, US New Home Sales Rise In February

CorMedix shares are trading lower. The company reported Q4 financial results.

<ul>
<li>CorMedix is announcing preliminary net revenue guidance for first half of 2025 of $50 – $60 million, based on the run rate of current purchasing customers, with more than $33 million expected in first quarter. In addition, the Company reiterates its previously announced cash operating expense guidance for 2025 of $72 – $78 million.</li>
</ul>

CorMedix Is Announcing Preliminary Net Revenue Guidance For First Half Of 2025 Of $50M–$60M

Cormedix (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CRMD#NASDAQ">CRMD</a>) reported quarterly earnings of $0.22 per share which beat the analyst consensus estimate of $0.14 by 57.14 percent. This is a 184.62 percent increase over losses of $(0.26) per share from the same period last year. The company reported quarterly sales of $31.21 million which beat the analyst consensus estimate of $26.53 million by 17.63 percent.

Cormedix Q4 2024 GAAP EPS $0.22 Beats $0.14 Estimate, Sales $31.21M Beat $26.53M Estimate

Press Releases

CorMedix Announces Collaboration for DefenCath Promotion to the VA and Other Federal Facilities

CorMedix Inc. to Report Fourth Quarter and Full Year 2024 Financial Results and Provide a Corporate Update on March 25, 2025

CorMedix Inc. Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update

Legal

INVESTOR ALERT: Investigation of CorMedix Inc. (CRMD) Announced by Holzer & Holzer, LLC

Kirby McInerney LLP Announces Investigation Against CorMedix Inc. (CRMD) on Behalf of Investors

CORMEDIX ALERT: Bragar Eagel & Squire, P.C. is Investigating CorMedix Inc. on Behalf of CorMedix Stockholders and Encourages Investors to Contact the Firm

CorMedix Inc. to Participate in the 24th Annual Needham Virtual Healthcare Conference

Cormedix Inc. Announces Preliminary First Quarter 2025 Results and Raises H1 2025 Net Sales Guidance

CorMedix Inc. to Report First Quarter 2025 Financial Results and Provide a Corporate Update on May 6, 2025

CorMedix Inc. Reports First Quarter 2025 Financial Results and Provides Business Update

Comments

Cormedix

뉴스

에 대한 최신 뉴스 Cormedix (NASDAQ:CRMD) 주식

목요일, 2월 20, 2025

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌